ArticleInternational ophthalmology2026
Impact of prostaglandin-related antiglaucoma medication use on levator aponeurosis advancement outcomes.
Article in International ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate postoperative eyelid height at 3 months after levator aponeurosis advancement with or without concomitant skin excision in eyes with and without prostaglandin-related antiglaucoma medication use.
methodsThis retrospective single-center study included patients who underwent levator aponeurosis advancement with or without concomitant skin excision for acquired ptosis. The primary outcome was postoperative margin reflex distance 1 (MRD-1) at 3 months. A linear mixed-effects model was used to evaluate factors associated with postoperative MRD-1, including prostaglandin-related antiglaucoma medication use and previous glaucoma surgery.
resultsSeventy-two eyes from 46 patients were analyzed; 35 received prostaglandin-related antiglaucoma medication, and 37 did not. Mean preoperative MRD-1 was significantly lower in the medication group (0.30 ± 0.82 mm vs 0.85 ± 0.83 mm, P = 0.006). Postoperative MRD-1 at three months did not differ significantly between groups. MRD-1 improvement was greater in the medication-use group (P = 0.024). Prostaglandin-related medication use was not significantly associated with postoperative MRD-1 after adjustment for preoperative MRD-1, age, sex, concomitant skin excision, and previous glaucoma surgery.
conclusionEyes administered prostaglandin-related antiglaucoma medication had a lower preoperative MRD-1 than eyes without such medication use. However, postoperative MRD-1 at 3 months was comparable between the groups. Prostaglandin-related medication use was not significantly associated with postoperative MRD-1 after adjustment for previous glaucoma surgery and other covariates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.